Signatera™ in High Risk Breast Cancer
Signatera is a personalized, tumor-informed assay with the power to give you earlier, clearer insight into your patient's disease. By detecting and quantifying ctDNA, Signatera can optimize your ability to assess risk, predict recurrence, and monitor treatment response in those most at risk for progression.
Signatera is a personalized, tumor-informed assay with the power to give you earlier, clearer insight into your patient's disease. By detecting and quantifying ctDNA, Signatera can optimize your ability to assess risk, predict recurrence, and monitor treatment response in those most at risk for progression.
In the Driver’s Seat with Signatera
When Rachelle was diagnosed with breast cancer at age 29, she was a young entrepreneur determined not to let her diagnosis define her. Her passion helped her maintain perspective as she and her doctor created a treatment plan.
Learn how Rachelle worked to integrate Signatera into her care plan and how she became a dedicated patient advocate along the way.
“The confidence of [getting tested with] Signatera allows me to live my best life every day.”
– Rachelle – entrepreneur, advocate, and breast cancer survivor
Unparalleled Insight in High Risk Breast Cancer
Signatera can detect recurrence up to 2 years earlier than traditional imaging.1
Signatera predicts breast cancer recurrence earlier and with greater accuracy than traditional tools by using a highly-personalized molecular residual disease assay.1
Signatera on Radio
Listen to Natera Leadership discuss how Signatera can help breast cancer patients on Into Tomorrow with Dave Graveline
Signatera on Radio
Listen to a recent story from NPR about how Signatera can be used in different tumor types
Is Signatera right for your patients?
We’re here to help you find out
References
1Coombes RC, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res. 2019 Jul 15;25(14):4255-4263. https://doi.org/10.1158/1078-0432.CCR-18-3663